var data={"title":"Gadobutrol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Gadobutrol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/331050?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=gadobutrol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Gadobutrol: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49334641\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Gadolinium-Based Contrast Agents Safety Alert</span>\n      <span class=\"collapsible-date\">December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;margin-top:2em;\">The FDA is requiring a new class warning, new Medication Guide, and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) regarding gadolinium remaining in patients' bodies, including the brain, for months to years after receiving these drugs. However, because gadolinium retention has not been directly linked to adverse health effects in patients with normal kidney function, the FDA has concluded that the benefit of all approved GBCAs continues to outweigh any potential risks.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Health care providers should consider the retention characteristics of each agent when choosing a GBCA for patients who may be at higher risk for gadolinium retention, including those requiring multiple lifetime doses, pregnant women, children, and patients with inflammatory conditions. Although providers should minimize repeated GBCA imaging studies when possible, particularly closely spaced MRI studies, necessary GBCA MRI scans should not be avoided or deferred. Health care providers should ensure that patients carefully read the new Medication Guide before receiving a GBCA.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Further information can be found at <a target=\"_blank\" href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm589580.htm&amp;token=Do7F8mUMHZ5/s1VO2ToSVQc0FIvxuJct8s2XQAmrP6Zclph1jTE4ohbEGIUswzhaMGIPSHysMdF12NhZ7JwyN2R2Gou2JaOgN/abp607dqC+GD0vx8r77GARzw9XI5at9GGki/68NHngWSah5+Qw3g==&amp;TOPIC_ID=8632\" target=\"_blank\">https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm589580.htm</a>.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Gadolinium-Based Contrast Agents for MRI Safety Review</span>\n      <span class=\"collapsible-date\">May 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The FDA identified no evidence to date that gadolinium retention in the brain from any of the gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) is harmful, including GBCAs associated with higher retention of gadolinium, and therefore, restricting GBCA use is not warranted at this time. All GBCAs may be associated with some gadolinium retention in the brain and other body tissues. The FDA will continue to assess the safety of GBCAs and plan to have a public meeting to discuss this issue in the future. Health care providers should limit GBCA use to circumstances in which additional information provided by the contrast agent is necessary, and assess the necessity of repetitive MRIs with GBCAs. Retention of gadolinium affects only GBCAs, and does not apply to other types of scanning agents used for other imaging procedures, such as those that are iodine-based or radioisotopes.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at <a target=\"_blank\" href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm559709.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery&amp;token=A+6oUwz5nYUZc3lEr1kP7BtLKnUrs6ODZsjcPV9KMyX4JnZOaUZ4v4WHkLmi0EKWvCCQ6RRR7uNYUokCfgeVc768Ba4J+HWDjLlRBCiBxtRZyZ58s7DOgXBX5msP35tg66ICqZf/qPRDl03GsgPnru8Lm2GCbUta4wNEC7od5KHrTCF6F4YU6ugBKJqroXAu&amp;TOPIC_ID=8632\" target=\"_blank\">https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm559709.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13478027\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Nephrogenic systemic fibrosis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of gadolinium-based contrast agents in these patients unless the diagnostic information is essential and not available with noncontrasted magnetic resonance imaging (MRI) or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The risk for NSF appears highest among patients with chronic, severe kidney disease (glomerular filtration rate [GFR] &lt;30 mL/minute/1.73 m<sup>2</sup>) or acute kidney injury.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (eg, &gt;60 years, hypertension, diabetes), estimate the GFR through laboratory testing.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">For patients at highest risk for NSF, do not exceed the recommended gadobutrol dose and allow a sufficient period of time for elimination of the drug from the body prior to any readministration.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12765549\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Gadavist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174308\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Gadovist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174312\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Diagnostic Agent;</li>\n      <li>\n        Gadolinium-Containing Contrast Agent;</li>\n      <li>\n        Radiological/Contrast Media (Nonionic, High Osmolality);</li>\n      <li>\n        Radiological/Contrast Media, Paramagnetic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5175443\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Diagnostic imaging:</b> IV: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i> Breast malignancy imaging, CNS imaging, and supra-aortic or renal artery angiography: 0.1 mmol/kg (0.1 mL/kg); may begin imaging immediately after administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Breast malignancy imaging: Usual dose: 0.1 mmol/kg (0.1 mL/kg); maximum: 0.3 mmol/kg (0.3 mL/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CNS imaging:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">General imaging: 0.1 mmol/kg (0.1 mL/kg); if needed, a second dose of 0.1 to 0.2 mmol/kg (0.1 to 0.2 mL/kg) may be repeated once within 30 minutes of the first dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Exclusion of metastatic or recurrent tumors: 0.3 mmol/kg (0.3 mL/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Perfusion studies: 0.1 to 0.3 mmol/kg (0.1 to 0.3 mL/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CE-MRA: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Imaging of a single field of view (FOV):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &lt;75 kg: 7.5 mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &ge;75 kg: 10 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Imaging &gt;1 FOV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &lt;75 kg: 15 mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &ge;75 kg: 20 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal imaging: Usual dose: 0.1 mmol/kg (0.1 mL/kg); maximum: 0.3 mmol/kg (0.3 mL/kg)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50991467\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">Dose adjustment is not recommended; however, use with caution. Risk for NSF development increases as renal function decreases.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Hemodialysis: If administered to patients already receiving hemodialysis, consider prompt hemodialysis following exposure. Data has shown hemodialysis enhances gadolinium elimination with average gadolinium excretory rates of 78%, 96%, and 99% in the first, second, and third hemodialysis sessions, respectively (Okada, 2001). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Peritoneal dialysis: Likely to be less efficient at clearing gadolinium (Joffe, 1998; Kuo, 2007). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50988793\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, based on exclusive renal excretion of gadobutrol, dose adjustment in hepatic impairment is likely unnecessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13362717\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Diagnostic imaging:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i>  CNS imaging, supra-aortic or renal artery angiography: Neonates, Children, and Adolescents: Refer to adult dosing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> CNS imaging/CE-MRA or renal imaging: Newborns, Infants, Children, and Adolescents: 0.1 mmol/kg (0.1 mL/kg); do not exceed recommended dose. Sequential or repeat dosing has not been studied; allow &ge;7 days before considering repeat administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112162\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">Dose adjustment is not recommended; however, use with caution. Risk for nephrogenic systemic fibrosis (NSF) development increases as renal function decreases.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dialysis: There are no pediatric specific recommendations; based on experience in adult patients the following has been observed:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: If administered to patients already receiving hemodialysis, consider prompt hemodialysis following exposure. Data has shown hemodialysis enhances gadolinium elimination with average gadolinium excretory rates of 78%, 96%, and 99% in the first, second, and third hemodialysis sessions, respectively (Okada 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peritoneal dialysis: Likely to be less efficient at clearing gadolinium (Joffe 1998; Kuo 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112163\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, based on exclusive renal excretion of gadobutrol, dose adjustment in hepatic impairment is likely unnecessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5175444\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12765550\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gadavist: 1 mmol/mL (2 mL, 7.5 mL, 10 mL, 15 mL, 30 mL, 65 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174310\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5175447\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Do not administer other medications in the same IV line simultaneously.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast malignancy imaging:</b> Administer as an IV bolus by power injector, followed by NS flush. Post contrast MRI can commence immediately following contrast administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Central nervous system imaging:</b> Administer as an IV injection, manually or by power injector, at a rate of ~2 mL/second, followed by a NS flush. Post contrast MRI can commence immediately following contrast administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Supra-aortic or renal artery angiography:</b> Image acquisition should coincide with peak arterial concentration, which varies among patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Adult:</i> Administer by power injector, at a rate of ~1.5 mL/second, followed by a 30 mL NS flush at the same rate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pediatric:</i> Administer manually or by power injector; followed by a NS flush.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling:</i> For perfusion studies, automatic injector is recommended at an infusion rate of 3 to 5 mL/second</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; initiate hyaluronidase antidote; elevate extremity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hyaluronidase: Intradermal or SubQ: Inject a total of 1 mL (15 units/mL) as five separate 0.2 mL injections (using a 25-gauge needle) into area of extravasation at the leading edge in a clockwise manner (MacCara 1983; Zenk 1981) or injection of a total of 5 mL (150 units/mL) as five separate 1 mL injections around the extravasation site has been also used successfully (Rowlett 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174314\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>US labeling: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Central nervous system (CNS) imaging:</b> Magnetic resonance imaging (MRI) in adults, adolescents, and pediatric patients (including term neonates) to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the CNS.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Breast malignancy imaging:</b> Contrast medium for use with MRI to assess the presence and extent of malignant breast disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Supra-aortic or renal artery angiography:</b> Magnetic resonance angiography (MRA) in adult and pediatric patients (including term neonates) to evaluate known or suspected supra-aortic or renal artery disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>\n        <i>Canadian labeling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Breast malignancy imaging:</b> Contrast medium for use with MRI to assess the presence and extent of malignant breast disease. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Central nervous system (CNS) imaging:</b> Contrast medium for magnetic resonance imaging (MRI) of CNS lesions (brain, spine, and associated tissues) and for perfusion studies to diagnose stroke, or to detect focal cerebral ischemia or tumor perfusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Contrast-enhanced magnetic resonance angiography:</b> Contrast medium for contrast-enhanced magnetic resonance angiography (CE-MRA).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Renal imaging:</b> Contrast medium for MRI of the kidney.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174304\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Gadavist may be confused with Magnevist</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gadovist [Canada and multiple international markets] may be confused with Vasovist brand name for gadofosveset [Hungary, Turkey] </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174709\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Allergic reaction, anaphylactoid reaction, cardiac arrest, convulsions, dizziness, dysgeusia, dyspnea, erythema, feeling hot, flushing, hypotension, injection site pain, injection site reaction, loss of consciousness, malaise, nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy (NSF/NFD), orthostatic hypotension, pallor, palpitation, paresthesia, parosmia, pruritus, seizure, sensation of cold, skin rash, tachycardia, urinary urgency, urticaria, vertigo, vision disturbance, vomiting, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174319\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">Severe hypersensitivity reactions to gadobutrol or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174320\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: High osmolar contrast agents are vesicants. Ensure proper needle or catheter placement prior to and during administration. Avoid extravasation; local tissue damage/reactions may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Anaphylactic and other hypersensitivity reactions (some fatal) have occurred (with mild to severe cardiovascular, respiratory or dermatologic involvement). Reactions typically occur within 30 minutes of administration; however, delayed reactions may also occur (up to several days following administration). Appropriate equipment (eg, ventilator) and emergency medications (eg, epinephrine) should be available during use. Use with caution in patients with a history of allergic reactions and/or bronchial asthma may be at an increased risk for developing hypersensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrogenic systemic fibrosis (NSF): <b>[US Boxed Warning]: Gadolinium-based contrast agent (GBCA) exposure increases the risk for NSF in patients with renal impairment; avoid use unless GBCA-enhanced imaging is essential for diagnostic purposes. The risk is highest in patients with acute kidney injury or chronic, severe renal disease (GFR &lt;30 mL/minute/1.73 m<sup>2</sup>).</b> The risk for NSF appears lower in patients with moderate, chronic renal disease (GFR 30 to 59 mL/minute/1.73 m<sup>2</sup>), and little, if any, in patients with mild, chronic renal disease (GFR 60 to 89 mL/minute/1.73 m<sup>2</sup>). In patients receiving hemodialysis, consider prompt initiation of hemodialysis following administration. If NSF occurs, report to manufacturer or the Food and Drug Administration (FDA).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">All patients should be screened for renal dysfunction prior to administration; estimate GFR in patients at risk for chronic renal disease (diabetes, chronic hypertension, age &gt;60 years). In patients at risk of NSF, do not exceed the recommended dosage and allow sufficient time (ie, several half-lives) for elimination prior to readministration (avoidance of readministration preferred). In patients receiving hemodialysis, consider prompt initiation of hemodialysis following administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment. Dose-dependent worsening of renal function or acute renal failure has occurred in patients with renal insufficiency following use of gadolinium agents, generally within 48 hours following administration. In patients with chronically reduced renal function, acute kidney injury requiring dialysis has occurred. Evaluate renal function in patients with renal impairment prior to use; consider follow-up monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients with a history of seizure disorder; may lower seizure threshold. Injectable anticonvulsant agents should be readily available.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Scan interpretation: Certain lesions may not appear with contrast-enhanced scan that do appear with noncontrast imaging; use caution when interpreting. Overestimation of extent of malignant disease in MRI of the breast has occurred in up to 50% of patients. A negative MRA study alone should not be used to rule out significant stenosis; performance of MRA for detecting arterial segments with significant stenosis (&gt;50% renal, &gt;70% supra-aortic) has not been shown to exceed 55%.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299376\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174716\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8632&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174315\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies. Gadnolinium-based contrast agents cross the placenta; in general, their use in pregnant women is controversial (ACOG 2016). Use should be avoided unless critical for the care of the mother or fetus, and it is not prudent to wait until after pregnancy. Agents with a low risk for development of nephrogenic systemic fibrosis should be used at the lowest effective dose (ACR 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174318\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Gadnolinium-based contrast agents are excreted into breast milk (ACR 2015). Some manufacturers recommend discontinuing breast-feeding for up to 24 hours following administration and discarding milk for that period. Because of the low expected excretion into breast milk and the low absorption from an infant&rsquo;s GI tract, other sources note that breast-feeding may be continued without interruption after use (ACOG 2016; ACR 2015). Theoretically, the taste of milk could be altered if it contains contrast media. Women who prefer to temporarily withhold breast-feeding can pump and store milk prior to the procedure and abstain from breast-feeding for 12 to 24 hours (ACR 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5175450\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function; signs of hypersensitivity (during and for several hours after procedure); short- and long-term monitoring of signs and symptoms of NSF/NFD (eg, burning, itching, swelling, hardening and/or tightening of skin, joint stiffness, deep hip or rib bone pain, muscle weakness, limited range of motion, and/or yellowed/raised spots on whites of eye); monitor for signs/symptoms of extravasation.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5175439\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Gadobutrol is a gadolinium-containing, nonionic paramagnetic agent. Exposure to an external magnetic field induces a large local magnetic field in exposed tissues. This local magnetism disrupts water protons in the vicinity, resulting in a change in proton density and spin characteristics, which can be detected by the imaging device. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174740\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Rapid into extracellular space</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Not metabolized</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Normal renal function: ~1.5 to 2 hours; severe renal dysfunction (CrCl &lt;30 mL/minute):  17.6  hours (mean)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (&gt;90% as unchanged drug); feces (negligible)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51196082\" class=\"block phksp drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal function impairment: The elimination half-life was 5.8 hours in mild-to-moderately impaired patients (CrCl 30 to 80 mL/minute) and 17.6 hours in severely impaired patients not on dialysis (CrCl &lt;30 mL/minute). The mean AUC in patients with healthy renal function was 1.1 mmol&bull;h/L compared with 4 mmol&bull;h/L in patients with mild-to-moderate renal impairment, and 11.5 mmol&bull;h/L in patients with severe renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Geriatric: AUC was slightly higher and clearance slightly lower in elderly patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324143\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Gadavist Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mmol/mL (10 mL): $106.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5175456\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Gadovist (AT, AU, BE, BG, CH, CN, CU, CY, CZ, DE, DK, EC, EE, ES, FI, FR, GR, HN, HR, IE, IS, IT, JP, KR, KW, LB, LK, LT, LU, LV, MT, MY, NL, NO, NZ, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, TR, VN, ZA);</li>\n      <li>Hadovist (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee Opinion No. 656: guidelines for diagnostic imaging during pregnancy and lactation. <i>Obstet Gynecol</i>. 2016;127(2):e75-e80. doi:10.1097/AOG.0000000000001316.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadobutrol-drug-information/abstract-text/26942391/pubmed\" target=\"_blank\" id=\"26942391\">26942391</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. Version 10.1. http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20Manual/2015_Contrast_Media.pdf. Published 2015. Accessed April 15, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Balzer J, Loewe C, Davis K, et al, &ldquo;Safety of Contrast-Enhanced MR Angiography Employing Gadobutrol 1.0 M as Contrast Material,&rdquo; <i>Eur Radiol</i>, 2003, 13(9):2067-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadobutrol-drug-information/abstract-text/12928957/pubmed\" target=\"_blank\" id=\"12928957\">12928957</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bellin MF, Jakobsen JA, Tomassin I, et al. Contrast medium extravasation injury: guidelines for prevention and management. <i>Eur Radiol</i>. 2002;12(11):2807-2812.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadobutrol-drug-information/abstract-text/12386778/pubmed\" target=\"_blank\" id=\"12386778\">12386778</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gadavist (gadobutrol) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gadovist (gadobutrol) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; March 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goyen M, Lauenstein TC, Herborn CU, et al, &ldquo;0.5 M Gd Chelate (Magnevist&reg;) Versus 1.0 M Gd Chelate (Gadovist): Dose-Independent Effect on Image Quality of Pelvic Three-Dimensional MR-Angiography,&rdquo; <i>J Magn Res Imag</i>, 2001, 14(5):602-07.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadobutrol-drug-information/abstract-text/11747013/pubmed\" target=\"_blank\" id=\"11747013\">11747013</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grobner T, &ldquo;Gadolinium - A Specific Trigger for the Development of Nephrogenic Fibrosing Dermopathy and Nephrogenic Systemic Fibrosis,&rdquo; <i>Nephrol Dial Transplant</i>, 2006, 21(4):1104-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadobutrol-drug-information/abstract-text/16431890/pubmed\" target=\"_blank\" id=\"16431890\">16431890</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Joffe P, Thomsen HS, and Meusel M, &quot;Pharmacokinetics of Gadodiamide Injection in Patients With Severe Renal Insufficiency and Patients Undergoing Hemodialysis or Continuous Ambulatory Peritoneal Dialysis,&quot; <i>Acad Radiol</i>, 1998, 5(7):491-502.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadobutrol-drug-information/abstract-text/9653466/pubmed\" target=\"_blank\" id=\"9653466\">9653466</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuo PH, Kanal E, Abu-Alfa AK, et al, &quot;Gadolinium-Based MR Contrast Agents and Nephrogenic Systemic Fibrosis,&quot; <i>Radiology</i>, 2007, 242(3):647-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadobutrol-drug-information/abstract-text/17213364/pubmed\" target=\"_blank\" id=\"17213364\">17213364</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacCara ME. Extravasation: A Hazard of Intravenous Therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713-717.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadobutrol-drug-information/abstract-text/6628223/pubmed\" target=\"_blank\" id=\"6628223\">6628223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Okada S, Katagiri K, Kumazaki T, et al, &ldquo;Safety of Gadolinium Contrast Agent in Hemodialysis Patients,&rdquo; <i> Acta Radiol</i>, 2001, 42(3):339-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadobutrol-drug-information/abstract-text/11350296/pubmed\" target=\"_blank\" id=\"11350296\">11350296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reynolds PM, Maclaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadobutrol-drug-information/abstract-text/24420913/pubmed\" target=\"_blank\" id=\"24420913\">24420913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowlett J. Extravasation of contrast media managed with recombinant human hyaluronidase. <i>Am J Emerg Med</i>. 2012;30(9):2102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadobutrol-drug-information/abstract-text/22633726/pubmed\" target=\"_blank\" id=\"22633726\">22633726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomach B, Bremer C, Reimer P, et al, &ldquo;Pharmacokinetics of 1M Gadobutrol in Patients With Chronic Renal Failure,&rdquo; <i>Invest Radiol</i>, 2000, 35(1):35-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadobutrol-drug-information/abstract-text/10639034/pubmed\" target=\"_blank\" id=\"10639034\">10639034</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tremblay E, Th&eacute;rasse E, Thomassin-Naggara I, et al, &quot;Quality Initiatives: Guidelines for Use of Medical Imaging During Pregnancy and Lactation,&quot; <i>Radiographics</i>, 2012, 32(3):897-911.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadobutrol-drug-information/abstract-text/22403117/pubmed\" target=\"_blank\" id=\"22403117\">22403117</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang PI, Chong ST, Kielar AZ, et al, &quot;Imaging of Pregnant and Lactating Patients: Part 1, Evidence-Based Review and Recommendations,&quot; <i>AJR Am J Roentgenol</i>, 2012, 198(4):778-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadobutrol-drug-information/abstract-text/22451541/pubmed\" target=\"_blank\" id=\"22451541\">22451541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Webb JA, Thomsen HS, and Morcos SK, &quot;The Use of Iodinated and Gadolinium Contrast Media During Pregnancy and Lactation,&quot; <i>Eur Radiol</i>, 2005 15(6):1234-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadobutrol-drug-information/abstract-text/15609057/pubmed\" target=\"_blank\" id=\"15609057\">15609057</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8632 Version 113.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F49334641\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F13478027\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F12765549\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F5174308\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F5174312\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F5175443\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50991467\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50988793\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F13362717\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51112162\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51112163\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F5175444\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F12765550\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F5174310\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F5175447\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F5174314\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5174304\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F5174709\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F5174319\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F5174320\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299376\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F5174716\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5174315\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5174318\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F5175450\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F5175439\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F5174740\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Considerations\" href=\"#F51196082\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324143\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5175456\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8632|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=gadobutrol-patient-drug-information\" class=\"drug drug_patient\">Gadobutrol: Patient drug information</a></li></ul></div></div>","javascript":null}